HK Stock Market Move | PATEO (02889) Surges Over 8% in Afternoon Session, Secures First 8397 Design Win for Overseas First-Batch Models from a Leading Domestic New Energy OEM
PATEO (02889) surged over 8% in the afternoon session. As of press time, it rose 7.23% to HK$91.2, with a turnover of HK$57.3595 million.
PATEO (02889) rose over 8% in the afternoon session. As of press time, it was up 7.23% at HK$91.2, with a turnover of HK$57.3595 million.
On the news front, PATEO recently announced that the company has received a formal project designation notice from a leading domestic high-end new energy vehicle OEM, and has been selected for the first time as a supplier for the customer's new-generation overseas models under its flagship brand, responsible for the development and mass production delivery of high-end intelligent cockpit domain controllers and AI interaction systems based on Qualcomm's 8397 new-generation high-performance cockpit chip platform.
It is understood that this designation covers the first batch of models in the customer's overseas product matrix, and subsequent series of models under the same platform will also be based on this chip platform. The project's overseas scope covers major global regions including Europe, Central and South America and Canada, the Middle East, Asia-Pacific, Central Asia, Africa, and Oceania. This designation marks another substantial breakthrough in PATEO's globalization strategy.
Related Articles

China Nuclear Engineering Corporation (601611.SH): Signed the contract for the nuclear island installation project (Lots I and II) of Guangdong Taishan Nuclear Power Units 3 and 4

Gan & Lee Pharmaceuticals (603087.SH): Investigational Drug GLR1075 Injection Receives Clinical Trial Approval

Morgan Stanley: Huawei Ascend 960 SuperPoD adopts NPO optical interconnect; maintains "In-Line" rating for Greater China technology hardware industry
China Nuclear Engineering Corporation (601611.SH): Signed the contract for the nuclear island installation project (Lots I and II) of Guangdong Taishan Nuclear Power Units 3 and 4

Gan & Lee Pharmaceuticals (603087.SH): Investigational Drug GLR1075 Injection Receives Clinical Trial Approval

Morgan Stanley: Huawei Ascend 960 SuperPoD adopts NPO optical interconnect; maintains "In-Line" rating for Greater China technology hardware industry

RECOMMEND





